The effects of estrogen on pulmonary artery vasoreactivity a... : Critical Care Medicine The
effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary …

Pathophysiology of pulmonary arterial hypertension is based on three basic mechanisms:
thrombotic pulmonary vascular lesions, vasoconstriction and vascular remodeling. Platelets …

Sex differences exist in a variety of cardiovascular disorders. Sex hormones have been
shown to mediate pulmonary artery (PA) vasodilation. However, the effects of fluctuations in …

Recent clinical studies have shown a sex dimorphism of morbidity and mortality due to
shock, trauma, and sepsis, with females tolerating these insults better than males …

Background and purpose: Phosphodiesterase type‐5 (PDE5) inhibitors constitute a novel
and important therapeutic option for the treatment of pulmonary hypertension. The effects of …

Chronic estrogen exposure has been shown to affect pulmonary artery (PA) vasoreactivity.
However, the immediate effects of exogenously administered 17β-estradiol (E2) on …

Hypoxic pulmonary vasoconstriction (HPV) and pulmonary hypertension present a common
and formidable clinical problem for practicing thoracic, transplant, and trauma surgeons. The …

Both endothelial nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF)
are important vasodilators in pulmonary circulation. Sepsis is known to impair endothelium …

Endothelin-1 is a potent mediator of sepsis-induced pulmonary hypertension (PH). The
pulmonary vascular effects of selective blockade of endothelin receptor subtype A (ETAR) …

Hypoxic pulmonary vasoconstriction (HPV) and pulmonary hypertension present a common
and formidable clinical problem for practicing intensivists, thoracic, transplant, and trauma …